Anebulo Pharmaceuticals annual return on equity
2022
2023
2024
2025
Anebulo Pharmaceuticals Return on Equity (ROE) Growth & History (ANEB)
Anebulo Pharmaceuticals's return on equity was −109.69% for fiscal 2025.
View full Anebulo Pharmaceuticals company overviewAnebulo Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −109.69% | +4.11 pp |
| 2024 | 2024-06-30 | −113.80% | −22.39 pp |
| 2023 | 2023-06-30 | −91.42% | −53.99 pp |
| 2022 | 2022-06-30 | −37.42% | — |
Anebulo Pharmaceuticals quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2025-12-31 | −22.63% | +6.59 pp |
| Q1 2026 | 2025-09-30 | −20.18% | +56.89 pp |
| Q4 2025 | 2025-06-30 | −17.08% | +13.61 pp |
| Q3 2025 | 2025-03-31 | −11.79% | +17.03 pp |
| Q2 2025 | 2024-12-31 | −29.22% | +7.46 pp |
| Q1 2025 | 2024-09-30 | −77.07% | −50.86 pp |
| Q4 2024 | 2024-06-30 | −30.69% | −9.49 pp |
| Q3 2024 | 2024-03-31 | −28.83% | −9.16 pp |
| Q2 2024 | 2023-12-31 | −36.68% | −14.58 pp |
| Q1 2024 | 2023-09-30 | −26.21% | −10.93 pp |
| Q4 2023 | 2023-06-30 | −21.20% | −6.79 pp |
| Q3 2023 | 2023-03-31 | −19.66% | −9.26 pp |
| Q2 2023 | 2022-12-31 | −22.10% | −16.57 pp |
| Q1 2023 | 2022-09-30 | −15.28% | −7.76 pp |
| Q4 2022 | 2022-06-30 | −14.41% | +471.75 pp |
| Q3 2022 | 2022-03-31 | −10.40% | — |
| Q2 2022 | 2021-12-31 | −5.53% | — |
| Q1 2022 | 2021-09-30 | −7.52% | — |
| Q4 2021 | 2021-06-30 | −486.17% | — |
Anebulo Pharmaceuticals return on equity trends
Between the periods ended 2022-06-30 and 2025-06-30, Anebulo Pharmaceuticals's return on equity decreased from −37.42% to −109.69%, a change of −72.27 percentage points. The latest reported quarter, Q2 2026, shows −22.63%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anebulo Pharmaceuticals source filings ↗